Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $209.00 at JPMorgan Chase & Co.

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by JPMorgan Chase & Co. from $200.00 to $209.00 in a research report report published on Wednesday,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Needham & Company LLC lifted their target price on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. TD Cowen lowered their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $182.47.

Jazz Pharmaceuticals Stock Up 3.2 %

JAZZ stock opened at $144.17 on Wednesday. The stock has a market capitalization of $8.72 billion, a P/E ratio of 20.31, a PEG ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $148.06. The company has a 50 day moving average price of $125.42 and a two-hundred day moving average price of $118.44.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. CWA Asset Management Group LLC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter worth $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares in the last quarter. Centre Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the 4th quarter worth $9,335,000. Moloney Securities Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the 4th quarter worth $464,000. Finally, Pacer Advisors Inc. lifted its holdings in Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.